These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21627604)

  • 21. Feline Hypertrophic Cardiomyopathy: The Consequence of Cardiomyocyte-Initiated and Macrophage-Driven Remodeling Processes?
    Kitz S; Fonfara S; Hahn S; Hetzel U; Kipar A
    Vet Pathol; 2019 Jul; 56(4):565-575. PubMed ID: 30895910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR.
    Moravsky G; Ofek E; Rakowski H; Butany J; Williams L; Ralph-Edwards A; Wintersperger BJ; Crean A
    JACC Cardiovasc Imaging; 2013 May; 6(5):587-96. PubMed ID: 23582356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myocardial fibrosis in patients with symptomatic obstructive hypertrophic cardiomyopathy: correlation with echocardiographic measurements, sarcomeric genotypes, and pro-left ventricular hypertrophy polymorphisms involving the renin-angiotensin-aldosterone system.
    Blauwet LA; Ackerman MJ; Edwards WD; Riehle DL; Ommen SR
    Cardiovasc Pathol; 2009; 18(5):262-8. PubMed ID: 18835191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involvement of the -420C>G RETN polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Hernández-Romero D; Orenes-Piñero E; García-Honrubia A; Climent V; Romero-Aniorte AI; Martínez CM; García-Bautista M; Martínez M; Feliu E; González J; Cánovas S; Montero-Argudo JA; Valdés M; Marín F
    J Intern Med; 2015 Jul; 278(1):50-8. PubMed ID: 25476756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypertrophy and fibrosis in the cardiomyopathy of uremia--beyond coronary heart disease.
    Gross ML; Ritz E
    Semin Dial; 2008; 21(4):308-18. PubMed ID: 18627569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes.
    Tanaka A; Yuasa S; Mearini G; Egashira T; Seki T; Kodaira M; Kusumoto D; Kuroda Y; Okata S; Suzuki T; Inohara T; Arimura T; Makino S; Kimura K; Kimura A; Furukawa T; Carrier L; Node K; Fukuda K
    J Am Heart Assoc; 2014 Nov; 3(6):e001263. PubMed ID: 25389285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycogen storage diseases presenting as hypertrophic cardiomyopathy.
    Arad M; Maron BJ; Gorham JM; Johnson WH; Saul JP; Perez-Atayde AR; Spirito P; Wright GB; Kanter RJ; Seidman CE; Seidman JG
    N Engl J Med; 2005 Jan; 352(4):362-72. PubMed ID: 15673802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of percentage area of myocardial fibrosis and disarray in patients with classical form and dilated phase of hypertrophic cardiomyopathy.
    Iida K; Yutani C; Imakita M; Ishibashi-Ueda H
    J Cardiol; 1998 Sep; 32(3):173-80. PubMed ID: 9783238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Changes of left ventricular myocardial collagen fibers and osteopontin expression in hypertrophic cardiomyopathy].
    Tang DW; Lin GS; Huang JL; Liu C; Hao B; Yu YG; Kong XP; Quan L; Liao XB; Luo B
    Fa Yi Xue Za Zhi; 2012 Aug; 28(4):247-51. PubMed ID: 23033660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular targets and novel pharmacological options to prevent myocardial hypertrophic remodeling].
    Coppini R; Ferrantini C; Poggesi C; Mugelli A; Olivotto I
    G Ital Cardiol (Rome); 2016 Mar; 17(3):189-96. PubMed ID: 27029877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution and clinical importance of fibrosis in HCM.
    Quarta G; Grasso A; Pasquale F; Flett AS; Sado DM; Bonini E; Ariti C; Prasad SK; Elliott PM; Moon JC
    JACC Cardiovasc Imaging; 2011 Nov; 4(11):1221-3. PubMed ID: 22093275
    [No Abstract]   [Full Text] [Related]  

  • 32. Proliferative Potential of Cardiomyocytes in Hypertrophic Cardiomyopathy: Correlation with Myocardial Remodeling.
    Sukhacheva TV; Chudinovskikh YA; Eremeeva MV; Serov RA; Bockeria LA
    Bull Exp Biol Med; 2016 Nov; 162(1):160-169. PubMed ID: 27882462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations.
    Germans T; Wilde AA; Dijkmans PA; Chai W; Kamp O; Pinto YM; van Rossum AC
    J Am Coll Cardiol; 2006 Dec; 48(12):2518-23. PubMed ID: 17174192
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences.
    Olivotto I; Cecchi F; Camici PG
    Ital Heart J; 2004 Aug; 5(8):572-80. PubMed ID: 15554027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myocardial collagen deposition and inflammatory cell infiltration in cats with pre-clinical hypertrophic cardiomyopathy.
    Khor KH; Campbell FE; Owen H; Shiels IA; Mills PC
    Vet J; 2015 Feb; 203(2):161-8. PubMed ID: 25573453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypertrophic cardiomyopathy in man and cats.
    Maron BJ; Fox PR
    J Vet Cardiol; 2015 Dec; 17 Suppl 1():S6-9. PubMed ID: 26776595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
    Paulus WJ; Tschöpe C
    J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between septal strain rate and histopathology in symptomatic hypertrophic cardiomyopathy patients undergoing septal myectomy.
    Kobayashi T; Popovic Z; Bhonsale A; Smedira NG; Tan C; Rodriguez ER; Thamilarasan M; Lytle BW; Lever HM; Desai MY
    Am Heart J; 2013 Sep; 166(3):503-11. PubMed ID: 24016500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk stratification in hypertrophic cardiomyopathy: time for renewal?
    Pacileo G; Salerno G; Gravino R; Calabrò R; Elliott PM
    J Cardiovasc Med (Hagerstown); 2013 May; 14(5):319-25. PubMed ID: 22885536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative clinico-instrumental characteristics of different morphological variants of hypertrophic cardiomyopathy].
    Popov VG; Sedov VP; Gruzdev AK; Alushkov MV
    Kardiologiia; 1985 May; 25(5):14-9. PubMed ID: 4040586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.